Breakthrough Therapy Designation acknowledges the growing body of evidence that supports Calquence as a highly-selective Bruton tyrosine kinase
inhibitor with the potential to offer patients a new, differentiated, chemotherapy-free treatment option with a favourable safety profile.
With acalabrutinib, we have a compound that optimally targets Bruton tyrosine kinase
," said Andrew Mortlock, Chief Scientific Officer at Acerta Pharma.
At the end of a 24-week, open-label trial, patients taking the oral inhibitor of Bruton tyrosine kinase
(BTK) plus very-low-dose prednisone also experienced a mean 65% reduction in antidesmoglein antibodies, a key driver of the sometimes-fatal blistering disease, Deedee Murrell, MD, the lead investigator said at the annual meeting of the American Academy of Dermatology.
Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase
(BTK) inhibitor in development for the treatment of multiple B-cell cancers.
Ibrutinib is a bruton tyrosine kinase
(BTK) inhibitor approved for B cell malignancies.
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency with more than 600 mutations in Bruton tyrosine kinase
(Bkt) gene which are responsible for early-onset agammaglobulinemia and repeated infections.
Tam, "Cardiac side effects of Bruton tyrosine kinase
(BTK) inhibitors," Leukemia and Lymphoma, pp.
Ibrutinib is an oral inhibitor of Bruton tyrosine kinase
(BTK) recently approved for relapsing/refractory (R/R) patients with Chronic Lymphocytic Leukemia (CLL) and MCL [4, 5].
GENEVA -- An oral reversible Bruton tyrosine kinase
inhibitor known as PRN1008 showed promising efficacy and safety for the treatment of pemphigus vulgaris in an interim analysis of an ongoing small-to-date, open-label phase 2 study according to DeDee Murrell, MD.
It was reported yesterday that the US Food and Drug Administration (USFDA) has granted priority review to AstraZeneca, an Anglo-Swedish multinational pharmaceutical and biopharmaceutical company, over a new drug application for its Bruton tyrosine kinase
The product is a proprietary Bruton tyrosine kinase
inhibitor intended to treat B-cell malignancies.
23 October 2014 - US cancer genetic testing service provider NeoGenomics Inc (NASDAQ:NEO) disclosed Thursday the launch of new tests for the detection of mutations in the Bruton tyrosine kinase
(BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors, as well as the launch of a lymphoma profiling test predicting susceptibility to BTK inhibitors and testing for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.